HURA

MKT CAP:$150M

TuHURA Biosciences, Inc.

Market Cap

$150M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$2.68+$1.93 (+257.57%)

Apr 22, 2026

Company Details

TuHURA Biosciences, Inc. is a phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company is headquartered in Tampa, FL.

CEO

James A. Bianco

IPO Date

Feb 22, 2013

Website

www.tuhurabio.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$22M

EPS (Diluted)

-$3.43

Free Cash Flow

-$20M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q4 2025

May 15, 2026

PENDING

FY 2025

Mar 31, 2026

$0EPS -$0.63

Q3 2025

Nov 14, 2025

$0EPS -$0.14

Q1 2025

May 15, 2025

$0EPS -$0.15

FY 2024

Dec 31, 2024

$0EPS -$1.21

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q3 21	$0	-$15.0K	-$6M
Q4 21	$0	-$15.0K	-$6M
Q1 22	$0	-$15.0K	-$5M
Q2 22	$0	-$15.0K	-$5M
Q3 22	$0	-$15.0K	-$5M
Q4 22	$0	-$15.0K	-$3M
Q1 23	$0	$0	-$19M
Q2 23	$0	-$15.0K	-$3M
Q3 23	$0	$0	-$4.6K
Q4 23	$0	-$15.0K	-$1M
Q1 24	$0	$0	-$5M
Q2 24	$0	$0	-$4M
Q3 24	$0	$0	-$2M
Q4 24	$0	-$17.6K	-$6M
Q1 25	$0	$0	-$7M
Q3 25	$0	$0	-$7M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 21	-$5M	-$5M
Q2 21	-$5M	-$5M
Q3 21	-$5M	-$5M
Q4 21	-$5M	-$5M
Q2 22	-$5M	-$5M
Q3 22	-$6M	-$7M
Q4 22	-$2M	-$2M
Q1 23	-$3M	-$3M
Q2 23	-$2M	-$2M
Q3 23	$0	$0
Q4 23	-$2M	-$2M
Q1 24	-$4M	-$4M
Q3 24	-$2M	-$2M
Q4 24	-$3M	-$3M
Q1 25	-$5M	-$5M
Q3 25	-$11M	-$11M

Capital Expenditures

Quarter	CapEx
Q1 21	$8.0K
Q2 21	$0
Q3 21	$0
Q4 21	$0
Q2 22	$0
Q3 22	$232.0K
Q4 22	$0
Q1 23	$0
Q2 23	$0
Q3 23	$0
Q4 23	$20.0K
Q1 24	$0
Q3 24	$0
Q4 24	$21.4K
Q1 25	$42.7K
Q3 25	$4

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q3 21	—	+106.5%
Q4 21	—	+9.6%
Q1 22	—	-18.9%
Q2 22	—	-18.5%
Q3 22	—	-22.2%
Q4 22	—	-40.6%
Q1 23	—	+249.8%
Q2 23	—	-38.6%
Q3 23	—	-99.9%
Q4 23	—	-70.9%
Q1 24	—	-75.4%
Q2 24	—	+8.1%
Q3 24	—	+48332.4%
Q4 24	—	+458.9%
Q1 25	—	+52.4%
Q3 25	—	+86.0%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 21	$0	—
Q2 21	$0	—
Q3 21	$0	—
Q4 21	$0	—
Q2 22	$0	—
Q3 22	$0	—
Q4 22	$0	—
Q1 23	$169.6K	—
Q2 23	$0	—
Q3 23	$0	—
Q4 23	$0	—
Q1 24	$334.6K	—
Q3 24	$101.0K	—
Q4 24	$0	—
Q1 25	$1M	—
Q3 25	$2M	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q3 21	$4M	—	$2M
Q4 21	$4M	—	$2M
Q1 22	$3M	—	$2M
Q2 22	$4M	—	$1M
Q3 22	$3M	—	$1M
Q4 22	$2M	—	$1M
Q1 23	$2M	$924.2K	—
Q2 23	$2M	—	$1M
Q3 23	$3.5K	$1.1K	—
Q4 23	$111.0K	—	$893.0K
Q1 24	$4M	$1M	—
Q2 24	$3M	$795.7K	—
Q3 24	$252.0K	$2M	—
Q4 24	$4M	—	$2M
Q1 25	$5M	$2M	—
Q3 25	$5M	$2M	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$9M	$0	$9M
Q2 22	$12M	$0	$12M
Q3 22	$7M	$0	$7M
Q4 22	$5M	$0	$5M
Q1 23	$10M	$0	$10M
Q2 23	$2M	$0	$2M
Q3 23	$216.0K	$0	$216.0K
Q4 23	$658.0K	$0	$658.0K
Q1 24	$4M	$0	$4M
Q2 24	$5M	$0	$5M
Q3 24	$3M	$0	$3M
Q4 24	$13M	$0	$13M
Q1 25	$6M	$0	$6M
Q2 25	$9M	$0	$9M
Q3 25	$3M	$0	$3M
Q4 25	$4M	$0	$4M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q3 21	20K	+4.7%	+100.4%
Q4 21	28K	+41.6%	+95.3%
Q1 22	28K	+1.2%	+67.8%
Q2 22	37K	+33.4%	+100.2%
Q3 22	42K	+11.7%	+113.5%
Q4 22	47K	+12.2%	+69.3%
Q1 23	48K	+2.3%	+71.1%
Q2 23	48K	+0.7%	+29.1%
Q3 23	49K	+1.5%	+17.3%
Q4 23	124K	+152.4%	+164.0%
Q1 24	348K	+180.7%	+624.2%
Q2 24	2M	+354.3%	+3168.7%
Q3 24	2M	+38.1%	+4345.2%
Q4 24	42M	+1839.8%	+34055.8%
Q1 25	43M	+2.6%	+12379.1%
Q3 25	51M	+16.7%	+3106.4%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q3 21	$0	4
Q4 21	$0	4
Q1 22	$0	4
Q2 22	$0	3
Q3 22	$0	3
Q4 22	$0	3
Q1 23	$0	3
Q2 23	$0	2
Q3 23	$0	2
Q4 23	$0	2
Q1 24	$0	2
Q2 24	$0	1
Q3 24	$0	1
Q4 24	$0	19
Q1 25	$0	19
Q3 25	$0	19

Revenue / Employee